Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections

Abstract

Two doses of dalbavancin (1000 mg given on day 1 followed by 500 mg given on day 8) were as well tolerated and as effective as linezolid given twice daily for 14 days for the treatment of patients with complicated SSSI, including those infected with MRSA.

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

“…A key issue with linezolid, however, is toxicity. Although a number of large postmarketing studies have found linezolid toxicity rates to be similar to those of comparator drugs (140,145,285,382), high rates of toxicity have been found for complex patients, and prolonged therapy should be used with caution in these cases (24).…”

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

“…Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including MRSA, VISA, and non-VanA strains of VRE; and clinical data indicate that dalbavancin is a safe, effective, and well-tolerated therapy for cSSTIs Streit et al 2004;Jauregui et al 2005). US Food and Drug Administration approval is expected in 2007.…”

“…The safety and effi cacy of dalbavancin has been examined in three clinical trials Raad et al 2005;Jauregui et al 2005). These trials include: one Phase II investigation that examined tolerability and effi cacy in catheterrelated gram-positive bloodstream infections (CR-BSI) (Raad et al 2005); and two trials (one Phase II and one Phase III) that evaluated dalbavancin in the treatment of skin and soft-tissue infection (SSTI) Jauregui et al 2005).…”

“…In the only published Phase III investigation, Jauregui et al compared dalbavancin with linezolid for the treatment of cSSTIs (Jauregui et al 2005). In this double-blind, randomized, multicenter trial, 854 adult patients were enrolled with a 2:1 randomization scheme.…”

Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment

“…Tedizolid could become a useful option for the treatment of acute bacterial skin and skin-structure infections in the hospital and outpatient settings (6). Studies have shown that the efficacy of dalbavancin administered once weekly, Oritavancin single dose and tedizolid 200 mg daily for 6 days are not inferior to that of a conventional twice daily antibiotic regimen with vancomycin or other glycopeptides and the early primary end point of cessation of the spread of infection and the absence of fever showed a consistent treatment effect regarding a reduction in the area of infection (4)(5)(6). Patients treated with dalbavancin had fewer adverse events than those treated with vancomycin and linezolid.…”